Terms: = Liver cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Prognosis
4779 results:
1. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
3. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
4. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.
Zhu JQ; Liu JZ; Yang SW; Ren ZY; Ye XY; Liu Z; Li XL; Han DD; He Q
Front Endocrinol (Lausanne); 2024; 15():1306091. PubMed ID: 38686208
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of bulk and single-cell transcriptomic data reveals a novel signature associated with endoplasmic reticulum stress, lipid metabolism, and liver metastasis in pancreatic cancer.
Liu X; Ren B; Fang Y; Ren J; Wang X; Gu M; Zhou F; Xiao R; Luo X; You L; Zhao Y
J Transl Med; 2024 Apr; 22(1):393. PubMed ID: 38685045
[TBL] [Abstract] [Full Text] [Related]
6. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
7. Brain radiotherapy and anlotinib control primary cardiac angiosarcoma with metastases: A case report.
Ma YY; Li ZK; Liao ZY; Peng Y; Zeng L; Ma DY
Medicine (Baltimore); 2024 Apr; 103(17):e37914. PubMed ID: 38669418
[TBL] [Abstract] [Full Text] [Related]
8. Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging.
Dong H; Yang L; Shaofeng D; Lili G
Technol Cancer Res Treat; 2024; 23():15330338241245943. PubMed ID: 38660703
[TBL] [Abstract] [Full Text] [Related]
9. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
[TBL] [Abstract] [Full Text] [Related]
10. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
[TBL] [Abstract] [Full Text] [Related]
11. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
12. DNA-based molecular classifiers for the profiling of gene expression signatures.
Zhang L; Liu Q; Guo Y; Tian L; Chen K; Bai D; Yu H; Han X; Luo W; Feng T; Deng S; Xie G
J Nanobiotechnology; 2024 Apr; 22(1):189. PubMed ID: 38632615
[TBL] [Abstract] [Full Text] [Related]
13. Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
Hao X; Xu L; Lan X; Li B; Cai H
BMC Cancer; 2024 Apr; 24(1):475. PubMed ID: 38622578
[TBL] [Abstract] [Full Text] [Related]
14. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.
Deng Z; Zhang W; Peng J; Gao L; Zhang C; Lei K; Gong J; Xiong B
Cardiovasc Intervent Radiol; 2024 May; 47(5):592-603. PubMed ID: 38605220
[TBL] [Abstract] [Full Text] [Related]
15. Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.
Xiong Y; Qiao W; Wang Q; Li K; Jin R; Zhang Y
Front Immunol; 2024; 15():1357496. PubMed ID: 38601167
[TBL] [Abstract] [Full Text] [Related]
16. Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS.
Liang Y; Liu Z; Zuo D; Chen S; Chen J; Yan X; Liu P; Wang Q
Talanta; 2024 Jul; 274():126056. PubMed ID: 38599123
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.
Chen X; Mohammed AF; Li C
Clin Appl Thromb Hemost; 2024; 30():10760296231221535. PubMed ID: 38591958
[TBL] [Abstract] [Full Text] [Related]
19. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract] [Full Text] [Related]
20. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].
Zheng XR; Peng JX; Song X; Liu B; Zhong C; Chen XY; Zhang BX; Peng L; Zhu KS; Xie C
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1160-1167. PubMed ID: 38583047
[No Abstract] [Full Text] [Related]
[Next]
